secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001193125-23-044164
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q4 revenue flat YoY at $186.8M; guides 2023 revenue down 5% to $760-800M
--------------------------------------------------------------------------------

- Q4 GAAP EPS $0.85 (up from $0.50 YoY); adjusted EPS $0.68 (down from $0.81).
- Full year 2022 revenue $801.5M (+20% YoY); base organic growth 39%.
- 2023 guidance: revenue $760-800M (down from 2022 due to $100-110M COVID decline); base organic growth 12-16%.
- Gross margin declines: Q4 GAAP 51.4% (down 460 bps), full year 56.9%; 2023 guided 52.5-53.5%.
- Launched 10 new products in 2022; cell/gene therapy revenue grew >50%; signed 2 partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312523044164/0001193125-23-044164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312523044164/d457202d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-044164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer